Fineline Cube

Follow:
14489 Articles
NHC Releases Standardized Family Doctor Service Packages for Key Demographic Groups
Policy / Regulatory

NHC Releases Standardized Family Doctor Service Packages for Key Demographic Groups

Kosell Medtech Partners with Wenzhou Medical University on K-Sheath System
CompanyDeals

Kosell Medtech Partners with Wenzhou Medical University on K-Sheath System

Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies
CompanyDrug

Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies

Hansoh Pharmaceutical Gains Clinical Approval for KRAS G12D Targeted Drug HS-10529
CompanyDrug

Hansoh Pharmaceutical Gains Clinical Approval for KRAS G12D Targeted Drug HS-10529

AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients
CompanyDrug

AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients

Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech
CompanyDeals

Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech

US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security
CompanyDrug

US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security

Johnson & Johnson Reports Q1 2025 Revenue Growth, Led by Innovative Medicines and MedTech
Company

Johnson & Johnson Reports Q1 2025 Revenue Growth, Led by Innovative Medicines and MedTech

BMS Faces Phase III Setback for Camzyos in Non-Obstructive HCM Study
CompanyDrug

BMS Faces Phase III Setback for Camzyos in Non-Obstructive HCM Study

Beijing Wantai Launches Phase III Trial for 9-Valent HPV Vaccine in Chinese Males
CompanyDrug

Beijing Wantai Launches Phase III Trial for 9-Valent HPV Vaccine in Chinese Males

Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA₂ Inhibitor for Alzheimer's Disease
CompanyDrug

Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA₂ Inhibitor for Alzheimer’s Disease

Hengrui Pharmaceuticals Gains NMPA Clearance for Phase II Study of HRS-7058 in Solid Tumors
CompanyDrug

Hengrui Pharmaceuticals Gains NMPA Clearance for Phase II Study of HRS-7058 in Solid Tumors